Clinical trials: Off-label Indications
Off-Label Use
Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe
This study is to characterize the indications for which rituximab is being used and to evaluate the use of the Patient Alert Card (PAC) in participants receiving the medication for non-oncology conditions at infusion centers.
- Trial name
- NCT02654379
- Testing
- Rituximab
- Where
- 48 sites in France, Germany and 3 more
- Volunteers
- 1,408 people
- Sponsor
- Hoffmann-La Roche
Transplant-Related Disorder, GVH - Graft Versus Host Reaction
Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use)
The protocol is designed to provide access to patients to the Clinimacs® CD34 TCRαβ system to prepare cells for an unlabeled indication using an HLA-compatible related or unrelated donor for allogenic transplant.
- Trial name
- NCT06393660
- Testing
- CliniMACS® CD34 TCR Alpha/Beta
- Where
- United States
- Sponsor
- Victor Aquino
Lymphoma, Leukemia
Managed Access Programs for CTL019, Tisagenlecleucel
The purpose of this registration is to list Managed Access Programs (MAPs) related to CTL019, Tisagenlecleucel
- Conditions
- Lymphoma, Leukemia, Off-label Indications
- Trial name
- NCT03601442
- Testing
- CTL019
- Sponsor
- Novartis Pharmaceuticals